Search clinical trials for: LY2541546 - SC

Total 523 results

AstraZeneca

Terminated

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

Crohn's Disease

United States, France, Italy, Belgium, Australia, Canada, Hungary, Russian Federation, Spain, Germany, Netherlands, Israel
Gilead Sciences

Completed

Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults

Ulcerative Colitis

New Zealand
PhaseBio Pharmaceuticals Inc.

Completed

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Type 2 Diabetes Mellitus

United States
Baxalta now part of Shire

Completed

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States
AbbVie

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Crohn's Disease

United States, Canada, Israel, Taiwan, Japan, Korea, Republic of
Eli Lilly and Company

Withdrawn

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (LUCENT-ACT)

Ulcerative Colitis
Zuyderland Medisch Centrum

Enrolling by invitation

Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease (SHUFFLE)

Crohn Disease | Ulcerative Colitis | IBD | Infliximab

Netherlands
Centocor, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease

Crohn Disease

United States, Canada, Belgium
GlaxoSmithKline

Completed

Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects

Systemic Lupus Erythematosus

China
Human Genome Sciences Inc.
GlaxoSmithKline

Terminated

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Mexico
Children's Hospital of Fudan University
RenJi Hospital; Shanghai Children's Hospital; Shanghai Children's Medical Center...

Terminated

Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children

COVID-19 | Children

China
Alexion

Completed

A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Shandong Cancer Hospital and Institute

Completed

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive (IMSLNB-CANP)

Breast Cancer

China
United BioPharma

Not yet recruiting

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

HIV-1-infection
Hoffmann-La Roche

Completed

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Follicular Lymphoma

United Kingdom, Belgium, United States, Australia, Canada, Germany
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...
Ministry of Health, Italy

Completed

Subthalamic Stimulation in Tourette's Syndrome (STN-DBSinTS)

Tourette Syndrome | Tourette's Syndrome | Tourette Disorder | Gilles de la Tourette Syndrome

Italy
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, Israel, Italy, Spain, United Kingdom
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
Northwestern University
University of Texas at Austin

Recruiting

Optimizing Outcomes for Young Autistic Children

Autism Spectrum Disorder | Autism

United States
AbbVie
Boehringer Ingelheim

Completed

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Belgium, Canada, Germany, Korea, Republic of, Netherlands, Poland, Spain, United Kingdom
UCB Pharma

Completed

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Rheumatoid Arthritis

United States, Belgium, United Kingdom
AbbVie

Completed

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
AbbVie
Boehringer Ingelheim

Completed

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Crohn Disease
Abbott

Completed

A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Medtronic Bakken Research Center

Completed

DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study (DATAS)

Ventricular Fibrillation | Ventricular Tachycardia | Defibrillators, Implantable
AbbVie

Completed

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
UCB Pharma

Completed

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

Arthritis | Rheumatoid Arthritis

United States, Germany
Hoffmann-La Roche

Active, not recruiting

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States, Israel, Spain, Korea, Republic of, Poland, Taiwan
Genentech, Inc.

Active, not recruiting

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic | Lymphoma, Non Hodgkin

United States, Korea, Republic of, Australia, United Kingdom, Germany, Canada, Spain
Bausch Health Americas, Inc.

Completed

Open-Label Treatment Extension of Protocol MNTX 302

Terminal Illness

United States
University Hospital, Bordeaux

Recruiting

Pharmacokinetics and Safety of Antimicrobial Agents Administered by Subcutaneous Route in Patients AGEd Over 65 Years (PhASAge)

Older People | Antimicrobials | Subcutaneous Injection | Antibiotic

France
Bausch Health Americas, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function

Liver Dysfunction

United States
Clearside Biomedical, Inc.

Completed

Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema (TYBEE)

Diabetic Macular Edema

United States
Bausch Health Americas, Inc.

Completed

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

Bowel Dysfunction

United States
Groupe d'Etude Therapeutique des Affections Inflammatoires...
Celltrion

Active, not recruiting

A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC (PEREM)

Inflammatory Bowel Diseases

France
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
Shandong Cancer Hospital and Institute

Completed

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative (IMSLNB-EBCP)

Breast Cancer

China
NeuroDerm Ltd.

Active, not recruiting

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

United States, Israel, Spain, France, Russian Federation, Austria, Italy, Belgium, Czechia, Hungary, Netherlands, Poland, Portugal, Slovakia, Ukraine, United Kingdom
AbbVie

Completed

Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis (PETAL)

Endometriosis
Fondazione Italiana Linfomi - ETS
Janssen-Cilag S.p.A.

Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (FIL_DALYA)

Plasmablastic Lymphoma

Italy
Bausch Health Americas, Inc.

Completed

Open-Label Treatment Extension of Protocol MNTX 301

Terminal Illness

United States
Chinese University of Hong Kong

Recruiting

Sensorimotor Block Dynamics and Hemidiaphragmatic Palsy: Selective Trunk Block vs Supraclavicular Brachial Plexus Block

Musculoskeletal Diseases or Conditions

Hong Kong
argenx

Recruiting

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD+)

Bullous Pemphigoid

Netherlands, Spain, Germany, United Kingdom, China, Italy, Hungary, United States, Croatia, Japan, Serbia, Bulgaria, Israel, Australia, Greece, Slovakia
University of Nebraska

Completed

Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients

Moderate to Advanced Chronic Periodontitis

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

IORT Versus CCRT for Pancreatic Cancer (IVCPC)

Pancreatic Cancer Stage IV

China
argenx

Active, not recruiting

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD)

Bullous Pemphigoid

United States, Australia, Bulgaria, China, Croatia, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Serbia, Slovakia, Spain, United Kingdom
Celgene

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)

United States
Gilead Sciences

Active, not recruiting

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection (PURPOSE 1)

Pre-Exposure Prophylaxis of HIV Infection

South Africa, Uganda
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

United States, Canada, Belgium, Spain, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Follicular Lymphoma

United Kingdom, United States, China, France, Spain

3

Subscribe